Literature DB >> 17187355

Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability.

Frank A Sinicrope1, Rafaela L Rego, Megan M Garrity-Park, Nathan R Foster, Daniel J Sargent, Richard M Goldberg, Myron Wiesenfeld, Thomas E Witzig, Stephen N Thibodeau, Lawrence J Burgart.   

Abstract

Colon cancers with microsatellite instability (MSI) demonstrate a host immune response characterized by tumor infiltrating lymphocytes (TILs) that may exert effects upon tumor cell apoptosis and cell proliferation. Accordingly, we compared rates of apoptosis and cell proliferation in colon cancers with defective DNA mismatch repair and their association with phenotypic features and clinical outcome. Primary Astler-Coller stage B2 and C colon carcinomas (n = 329) were analyzed for MSI and for hMLH1 and hMSH2 protein expression. Apoptosis (TUNEL assay) and p53 expression were also analyzed by immunohistochemistry, and TILs were quantified by morphology. DNA ploidy and proliferation (PI: S phase + G(2)M) were evaluated using flow cytometry. MSI-H (n = 58) colon cancers showed increased TILs that were significantly associated with increased apoptosis, higher apoptosis to proliferation (AI/PI) ratios, reduced proliferative indices (PI) and diploid DNA content. Increased TILs (p = 0.036) and reduced PI (p = 0.042), but not AI or AI/PI, were associated with improved disease-free survival. Tumors with MSI-H (p = 0.032) or loss of hMLH1 or hMSH2 proteins (p = 0.040), or diploidy (p = 0.0015), had better adjusted overall survival rates. Interestingly, similar rates of cell turnover and overlapping survival rates were found in diploid MSS/MSI-L tumors and in MSI-H cases. In conclusion, higher apoptosis/proliferation ratios and reduced cell proliferation are phenotypic features of MSI-H tumors that are associated with increased TILs, indicating an activated immune response that may contribute to their favorable survival rates. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17187355     DOI: 10.1002/ijc.22429

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).

Authors:  Harry H Yoon; David Tougeron; Qian Shi; Steven R Alberts; Michelle R Mahoney; Garth D Nelson; Suresh G Nair; Stephen N Thibodeau; Richard M Goldberg; Daniel J Sargent; Frank A Sinicrope
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

2.  Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas.

Authors:  Frank A Sinicrope; Thomas C Smyrk; David Tougeron; Stephen N Thibodeau; Shalini Singh; Andrea Muranyi; Kandavel Shanmugam; Thomas M Grogan; Steven R Alberts; Qian Shi
Journal:  Cancer       Date:  2013-05-08       Impact factor: 6.860

3.  Systemic Analysis of Predictive Biomarkers for Recurrence in Colorectal Cancer Patients Treated with Curative Surgery.

Authors:  Koichiro Mori; Yuji Toiyama; Susumu Saigusa; Hiroyuki Fujikawa; Junichiro Hiro; Minako Kobayashi; Masaki Ohi; Toshimitsu Araki; Yasuhiro Inoue; Koji Tanaka; Yasuhiko Mohri; Masato Kusunoki
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

4.  Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance).

Authors:  Frank A Sinicrope; Michelle R Mahoney; Harry H Yoon; Thomas C Smyrk; Stephen N Thibodeau; Richard M Goldberg; Garth D Nelson; Daniel J Sargent; Steven R Alberts
Journal:  Clin Cancer Res       Date:  2015-07-17       Impact factor: 12.531

5.  Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.

Authors:  Frank A Sinicrope; Michelle R Mahoney; Thomas C Smyrk; Stephen N Thibodeau; Robert S Warren; Monica M Bertagnolli; Garth D Nelson; Richard M Goldberg; Daniel J Sargent; Steven R Alberts
Journal:  J Clin Oncol       Date:  2013-09-09       Impact factor: 44.544

6.  Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications.

Authors:  Aziz Zaanan; Katy Meunier; Fatiha Sangar; Jean-François Fléjou; Françoise Praz
Journal:  Cell Oncol (Dordr)       Date:  2011-04-12       Impact factor: 6.730

Review 7.  Clinical implications of microsatellite instability in sporadic colon cancers.

Authors:  Frank A Sinicrope; Daniel J Sargent
Journal:  Curr Opin Oncol       Date:  2009-07       Impact factor: 3.645

8.  Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.

Authors:  R L Rego; N R Foster; T C Smyrk; M Le; M J O'Connell; D J Sargent; H Windschitl; F A Sinicrope
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

Review 9.  Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients.

Authors:  Kristen M Drescher; Poonam Sharma; Henry T Lynch
Journal:  Clin Dev Immunol       Date:  2010-06-10

10.  Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma.

Authors:  Frank A Sinicrope; Rafaela L Rego; Stephen M Ansell; Keith L Knutson; Nathan R Foster; Daniel J Sargent
Journal:  Gastroenterology       Date:  2009-07-03       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.